Arvinas Inc.
Nasdaq ARVN · New Haven, CT
Works in Dermatology · ENT · Genetic & rare · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Neurology · Oncology · Renal & urogenital · Respiratory · Women's health
Arvinas Inc. is a clinical trial sponsor based in New Haven, CT, listed as Nasdaq ARVN. It has 3 active clinical trials with 904 planned participants, across 13 therapeutic areas. Since 2021 it has completed 2 trials and stopped 0 early.
Trial track record · since 2021
Financials · Nasdaq ARVN
Pipeline · 3 active trials
| Stage | Trial | Status |
|---|---|---|
Questions about Arvinas Inc
Arvinas Inc is lead sponsor of 3 active clinical trials on ClinicalTrials.gov, with 904 planned participants, in Dermatology, ENT, Genetic & rare, GI & liver and other areas. Since 2021 it has completed 2 trials and stopped 0 early.
Arvinas Inc is based in New Haven, CT and is listed as Nasdaq ARVN. The address is the one on its SEC filings, which name the establishment or the registrant, not always the group's head office.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Arvinas Inc; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Arvinas Inc..
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.